

Media Release

Zug, 1 April 2026

Ad hoc announcement pursuant to Art. 53 LR

HBM Healthcare Investments increases NAV by 17.2 percent and expects annual profit of CHF 272 million for the 2025/2026 financial year

HBM Healthcare Investments, an investment company specializing in the healthcare sector, successfully closed its 2025/2026 financial year as of 31 March. Over the course of the year, the net asset value (NAV) in Swiss francs increased by 17.2 percent (29.2 percent in US Dollars), while the share price recorded an increase of 28.5 percent.

In addition to the constructive capital market environment for the biotechnology sector, the positive result was driven in particular by several value-enhancing transactions involving both private and publicly listed portfolio companies. During the financial year under review, a total of seven portfolio companies — Merus, Y-mAbs Therapeutics, 89Bio, Akero, Bluejay Therapeutics, Swixx Biopharma, and Terns Pharmaceuticals — were acquired by pharmaceutical companies or financial investors.

By contrast, the strong appreciation of the Swiss franc against the Company's main investment currencies had a noticeable negative impact on the annual result.

The figures presented are preliminary and unaudited, based on the current status of the year-end closing process. The final annual results will be published with the 2025/2026 Annual Report on 13 May 2026.

Contact

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative

to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to U.S. persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments Ltd's securities were not issued in accordance with the U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions.08/2025